Clinical Trial Update: Cell Bound Complement Activation Proteins as Markers of Liver Injury

View source ↗

Summary

A clinical trial evaluating cell-bound complement activation proteins as biomarkers of liver injury in Hepatitis C has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Snippet

Sponsor: University of Pittsburgh | Conditions: Hepatitis C | Status: WITHDRAWN